Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price
Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.
You may also be interested in...
UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
Amgen’s Q3 Sales Beat Consensus, But Two Key New Drugs Fell Short
Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.
Evenity Gets CHMP Nod On Second Pass
UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.